












































Citation for published version:
Razal, M, Chaudhry, U, Doerholt, K, Bauld, L & Majeed, A 2021, 'Covid-19 vaccination hesitancy', BMJ, vol.
373. https://doi.org/10.1136/bmj.n1138
Digital Object Identifier (DOI):
10.1136/bmj.n1138
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
 
Page 1 of 14 
Covid-19 vaccination hesitancy 1 
 2 
What you need to know 3 
 Lack of covid-19 vaccine confidence poses direct and indirect threats to health and could 4 
derail efforts to end the current pandemic  5 
 Vaccines’ safety, efficacy and importance could be communicated to individuals and 6 
communities, using a variety of evidence-based strategies outlined here, to enable 7 
informed decision-making  8 
 Tailored communication approaches to different groups to build confidence in vaccines 9 
and address the root causes of concerns are effective in increasing uptake. These include 10 
systemic and socioeconomic factors, improving access, provision of practical support and 11 
tackling misinformation through targeted public health campaigns  12 
 13 
 14 
Covid-19 vaccination rollout is well underway, with over 700 million doses given worldwide 15 
by April 2021.1 Vaccination is highly effective at reducing severe illness and death from Covid-16 
19. Covid-19 vaccines are also safe with extremely low risks of severe adverse events.2-4 For 17 
example, the risk of blood clots following AstraZeneca vaccine is estimated 4 per million 18 
people vaccinated.5 A major threat to the impact of vaccination in  preventing disease and death 19 
due to SARS-CoV-2 is low vaccine uptake. In this practice pointer, we offer on overview of 20 
vaccine hesitancy and some approaches that clinicians and policymakers can adopt at the 21 
individual and community level to help people make informed decisions about covid-19 22 
vaccination. 23 
 24 
What is vaccine hesitancy? 25 
The World Health Organization (WHO) defines vaccine hesitancy as a ‘delay in acceptance or 26 
refusal of safe vaccines despite availability of vaccine services.’6 It is caused  by complex, 27 
context-specific factors that vary across time, place and specific vaccines, and is influenced by 28 
issues such as complacency, convenience, confidence and socio-demographic contexts. 7 29 
Vaccine hesitancy may also be related to misinformation and conspiracy theories which are 30 
often spread online including through social media.8 9 However, structural factors including 31 
health inequalities, socioeconomic disadvantages, systemic racism and access barriers are key 32 
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drivers of low confidence in vaccines and poor take-up.6 10-12 Vaccine hesitancy, although 33 
widely used, is a problematic term that does not adequately reflect these wider determinants 34 
that influence  decisions to delay or refuse vaccination.  35 
 36 
How common is vaccine hesitancy? 37 
 38 
Vaccine hesitancy is a global problem.  Surveys report that between 50% to 60% of all 39 
respondents worldwide would be willing to receive a covid-19 vaccine in 2021 with wide 40 
variations across countries.13 14  In the UK, surveys have found variation in willingness to have 41 
a vaccine between ethnic groups. The UK Household Longitudinal survey asked (in November 42 
2021) 12035 participants "how likely or unlikely would you be to take the vaccine?" Overall 43 
only 18% of respondents were hesitant (answering unlikely or very unlikely), in contrast to 44 
high levels of hesitancy in people of black ethnicity (72%) followed by South Asians of 45 
Pakistani and Bangladeshi heritage (both 42%) and mixed ethnicities (32%); though levels of 46 
vaccine hesitancy were comparable to Whites in people of Chinese ethnicity, highlighting the 47 
heterogeneity between ethnic minorities.15  Recent data in the UK (as of 11 March 2021) reveal 48 
lower vaccination rates, among those eligible for vaccination, in Black African and Black 49 
Caribbean (58.8% and 68.7% respectively), Bangladeshi (72.7%) and Pakistani (74%) ethnic 50 
groups compared with White British (91.3%), and lower vaccination rates in people who live 51 
in more deprived areas (most deprived 87%, least deprived 92.1%).16  52 
 53 
Higher vaccine hesitancy is also reported amongst women (female 21%; male 15%), younger 54 
age groups (28% in 25-34 years versus 14% in 55-64 years), and people with a lower education 55 
level (24% in secondary school graduates; 13% in university graduates).15 These data follow a 56 
historical trend in the UK of lower uptake of pneumococcal, influenza, rotavirus and shingles 57 
vaccines among socioeconomically disadvantaged individuals 17-19 and ethnic minorities.12 20 58 
Similarly, a lower uptake has been observed with childhood immunisations in ethnic minority 59 
populations.12 Variation in covid-19 vaccination rates is also seen between religious groups. 60 
Vaccination rates have been lower in Muslim (72.3%), Buddhist (78.1%), Sikh (87%) and 61 
Hindu (87.1%) compared with Christian (91.1%) religious groups.16 In addition, individuals 62 
who are uncertain about receiving vaccination form a larger proportion than those who are 63 
unwilling (23% versus 14% respectively) and therefore a stronger group to focus a potential 64 
intervention.21 Nevertheless, it is very difficult to distinguish between these two groups; 65 
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therefore, public health campaigns should focus on providing information and increasing trust 66 
in the safety and efficacy of covid-19 vaccination amongst both these groups.21 67 
 68 
Vaccine hesitancy among healthcare workers (HCWs) is an area of particular concern due to 69 
their role as trusted sources of health information and in spreading healthcare-acquired 70 
infections. This is particularly the case in ethnic minority HCWs as they comprise a higher 71 
proportion of NHS workers in the UK compared to the working-age population. Recent data 72 
from one NHS trust shows lower covid-19 vaccination rates in ethnic minority HCWs (70.9% 73 
in white workers v 58.5% in South Asian and 36.8% in black workers; P<0.001 for both). 22 74 
Additionally, vaccine uptake in HCWs vary with previously reported low uptake (37%) of 75 
H1N1 vaccine amongst support staff.8  A quarter (26%) of NHS trusts in England did not reach 76 
70% coverage for seasonal influenza vaccination in HCWs in 2019-2020.12  77 
 78 
What are the causes of covid-19 vaccine hesitancy?  79 
 80 
Confidence in the importance of vaccines has the strongest association with vaccine take-up; 81 
however confidence in the importance (necessity and value), safety and effectiveness of 82 
vaccines fell in many countries between 2015 to 2019.23 This waning confidence in vaccines 83 
led the WHO to list vaccine hesitancy among the top ten global threats to health in 2019.24 84 
Drivers of low confidence in covid-19 vaccination are listed in box 1. A recent survey 85 
highlighted that the main reason for hesitancy were concerns about future unknown effects, 86 
with 42.7% of participants specifying this.15 Less common reasons included those under the 87 
bracket of ‘other’ (12.2%), worries about side effects (11.4%), other people in greater need 88 
given limited supply (7.7%) and lack of trust with vaccines (7.6%).15 However, black 89 
ethnicities were more likely to state that they ‘Don’t trust vaccines’ compared to whites (29.2% 90 
vs 5.7%) and people of Pakistani and Bangladeshi ethnicities cited concerns about vaccine side 91 
effects (35.4% vs 8.6%).15 Some reports indicate a rise in vaccine hesitancy following the 92 
AstraZeneca vaccine safety scare across Europe and Africa. 25 26 Historical precedents show 93 
that widely publicised safety scares can have profound and long-lasting impact on vaccine 94 
confidence.27  95 
 96 
 97 
Box 1 Causes and drivers of low confidence in covid-19 vaccines 6 8 10 12 28 98 
 99 
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 Socio-economic and healthcare inequalities and inequities  100 
 Structural racism and previously unethical research done on some ethnic minority groups  101 
 Social disadvantages including low level of education and poor access to accurate 102 
information 103 
 Misinformation, disinformation, rumours and conspiracy theories in particular through 104 
social media  105 
 Lack of effective public health messages or targeted campaigns  106 
 Access barriers including vaccine delivery time, location and cost related to socio-107 





Box 2 Stated reasons for low covid-19 vaccine take-up amongst the public23 29 30  113 
 114 
 Concerns about long-term effects, side effects and unknown future effects on health  115 
 Previous side effects to other routine vaccines such as influenza vaccine 116 
 Low confidence in vaccines, including their importance, safety and efficacy  117 
 Lack of trust in the manufacturing and country of production of vaccines, vaccine 118 
technology, the pharmaceutical industry, government and public health bodies  119 
 Concerns about the speed of development of covid-19 vaccines  120 
 Concerns about vaccines’ incompatibility with religious beliefs  121 
 Previously negative healthcare experiences including racial discrimination  122 
 Lower risk and perception of lower risk of covid-19 (especially amongst younger age 123 
groups)  124 
 Lack of communication from trusted providers and community leaders  125 
 Practical concerns such as inconvenient vaccine delivery time and location  126 
 Not offered vaccine due to inaccurate patient contact information 127 
 Direct and indirect costs of vaccine (in some low and middle income countries) .......) 128 
 Apprehensions surrounding fertility, pregnancy and breast-feeding 129 
 Belief in conspiracy theories such as covid-19 not being real, or that vaccines modify 130 
DNA 131 
 Recent  covid-19 infection 132 
 133 
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 134 
How to approach covid-19 vaccine hesitancy 135 
 136 
Approaching vaccine hesitancy is complex, and therefore no single intervention can address 137 
this entirely, especially in the context of covid-19 where evidence is currently limited.31 138 
Furthermore, these single approaches would be hard to apply in different settings and 139 
populations. When considering the most effective methods to increase vaccine uptake, these 140 
would be comprehensive multi-component approaches tailored to the local population 141 
combined with good communication at an individual level.31 At a broader national level, this 142 
would also include traditional media channels (for example, television, radio, public transport 143 
advertising and the internet) and social media campaigns using visually appealing short simple 144 
messages to engage different groups regarding public health policies and countering any mis-145 
information.32 33 146 
 147 
Recognition of barriers to uptake (box 2) is important to inform appropriate interventions to 148 
address them (box 3). Historically, interventions based on reminder/recall notifications have 149 
improved vaccination uptake amongst different groups and settings, although there is limited 150 
evidence to support their use specifically for addressing hesitancy.28 34 A multifaceted, non-151 
stigmatising approach is therefore needed to share communication (in a variety of mediums) 152 
from trusted sources.12 The key is to build confidence, particularly listening to people’s 153 
concerns, being respectful of different religious or cultural beliefs, and awareness of 154 
historically-rooted understandable mistrust, as well as other ethical considerations around 155 
clinical interventions.12 Vaccine-hesitant individuals are not ‘anti-vaxxers’ and this needs to be 156 
acknowledged. They will usually be open to engage in dialogue about vaccine safety, efficacy 157 





Box 3 Summary of strategies for interventions to increase vaccination uptake 12 31 35 163 
1. Tailored communication from trusted sources such as community representatives, 164 
healthcare providers and local authorities that is culturally relevant and accessible in 165 
multiple languages. And builds confidence in the importance, safety and effectiveness of 166 
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vaccines using different types of traditional media and social media, targeting 167 
misinformation and sharing success stories 168 
2. Access to community groups and local NHS services: ensuring convenience with vaccines 169 
being readily available; flexible delivery models in the community, GP surgery and 170 
outreach programmes; ensuring ease of transportation; directly targeting under-vaccinated 171 
populations 172 
3. Engagement by community champions, youth ambassadors, faith leaders, healthcare 173 
workers and regulators: raising knowledge and awareness on vaccinations; encouraging 174 
healthcare professionals to recommend covid-19 vaccination; celebrating household 175 
members, friends, relatives and role models being vaccinated; fostering an approach of 176 
community immunity and helping others; continuous, open and transparent dialogue with 177 
locally developed action plans 178 
4. Training and education of those involved with engagement activities at a local level: using 179 
relevant educational materials (eLearning modules) in presentations and communication 180 




Healthcare workers (HCWs) are the most trusted source of information on vaccination and can 185 
influence local vaccination rates through individual and population level approaches. At an 186 
individual level, effective communication that targets capability (knowledge and skills), 187 
opportunity (social norms and physical resources) and motivation (analytic decision-making 188 
and behaviours) will better convey health messages.36 HCWs working alongside local authority 189 
members, faith leaders and ‘Community Champions’ can facilitate engagement, guide 190 
household decision-makers and make vaccine recommendations.12 37 191 
 192 
Improving access and removing barriers 193 
 194 
Minimising practical obstacles to accessing covid-19 vaccination is crucial. Consider how one 195 
can improve convenience through multiple reminders to attend for vaccination and offering 196 
appointments outside of normal working hours in the evenings or weekends. People with 197 
disabilities or those who have been shielding may find it particularly hard to attend a 198 
vaccination appointment. Therefore, considering an individual’s distance to the vaccination 199 
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site, offering to arrange appropriate transportation or utilising home-visiting facilities can 200 
maximize access for these patients.12 Vaccination sites outside of formal healthcare settings 201 
such as community-based settings, places of worship and work-based environments can offer 202 
a degree of familiarity and enable reach within communities that distrust government or 203 
medical sources.37 They also offer the opportunity for peer support from friends, family 204 
members and colleagues who have agreed to be vaccinated. 205 
 206 
Community engagement and local-level interventions 207 
 208 
The WHO has proposed a number of recommendations that could be applied here in the context 209 
of covid-19 vaccinations31.Dialogue-based interventions promote discussions between those 210 
implementing desired strategies for vaccination and the target community. For covid-19 211 
vaccination, this would centre on involving appropriate religious or traditional community 212 
leaders, both male and female, who can engage key audiences through open discussion, 213 
advocacy and integrated community activities.28 Where appropriate, this could be alongside 214 
group discussions with HCWs in local settings to improve awareness, reinforce messages and 215 
promote consistency.28 31 32 Having readily available online material for HCWs and vaccine 216 
recipients, such as eLearning modules, that reinforces messaging behind vaccine safety and 217 
effectiveness can consolidate a unified approach in tackling hesitancy.32 218 
 219 
Setting a communication agenda through different forums can be an effective strategy to 220 
promote covid-19 vaccination. This should include active engagement from health, political, 221 
community, legal and academic representatives at a local level to help authorities understand 222 
relevant issues and build trust with community partners.36 Pre-testing and co-production of 223 
material, either written, audio or visual, could be translated into a range of suitable languages 224 
or in a format accessible to sub-groups, with cultural validation of health messages.36 225 
Resources specific to different sub-groups and those at higher risk of hesitancy, such as ethnic 226 
minority communities, pregnant women, faith groups and others should be readily available 227 
and easily accessible from a single source.35 38 The NHS Coronavirus (COVID-19) Resource 228 
Centre is a portal that contains downloadable material to support communications.39 These 229 
have been created in line with the governmental covid-19 vaccine action plan and a further 230 
framework to maximize uptake in underserved communities, which places an emphasis on 231 
community engagement using relevant case studies as examples.40 41  232 
 233 
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 234 
Policy makers and other relevant stakeholders could use online platforms at a community level 235 
to provide factual information and build confidence amongst marginalized sub-groups.21 42 236 
Recent evidence from two pilot programmes in California has emphasized the importance of 237 
community engagement, in addressing disparities in covid-19 transmission.43 They 238 
demonstrated that having multilingual, culturally-sensitive information delivered by 239 
empowered community spokespeople at mobile testing sites can maximize participation, 240 
address these inequalities and be translated as part of a local covid-19 vaccination strategy.43 241 
44 These interventions (box 3) will need careful evaluation by policymakers to identify those 242 
that have worked well and those that require strengthening.12 Regular reporting of vaccine 243 
uptake at a local level by different population demographics, including ethnicity, can help to 244 




Communicating vaccination with a patient 249 
 250 
Discussion and engagement with vaccine-hesitant patients should be conducted in an open, 251 
honest and non-judgemental manner (boxes 5 and 6).45 The literature refers to any discussion 252 
between those implementing a strategy and the target community as a dialogue-based 253 
individual-level intervention28; for example, actively calling patients who have not received a 254 
vaccine. Various approaches have been studied, some incorporating online or paper-based 255 
resources to inform patients of perceived benefits and safety issues. One simple example is the 256 
‘elicit-share-elicit’ approach.35 The HCW asks open-ended questions to identify concerns and 257 
then offers to share their expertise about this concern by providing solicited explanations to 258 
any myths or fallacies. Tailored education based on self-reported race, specific attitudes and 259 
previous experiences have also been shown to be beneficial.45 . This maintains an empathetic 260 
relationship, whilst also providing an opportunity to communicate risk and support decision-261 
making. There is however currently a lack of evidence as to whether different HCWs versus 262 
allied staff in administrative roles who discuss vaccination has an overall impact on uptake. 263 
When responding to legitimate concerns regarding the speed of the vaccine roll-out, HCWs 264 
could highlight the accelerated collaborative international drive that has taken place, which has 265 
occurred without compromising on scientific rigour to establish safety and efficacy, and will 266 
be continuously monitored by regulators. Recent concerns over a possible link between 267 
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coronavirus vaccines and rare blood clots demonstrate that this monitoring is taking place, and 268 
can even detect serious side effects as rare as one in 250,000 people vaccinated.46 This process 269 
of identifying patients’ ideas or concerns is a core communication skill for any HCW and is in 270 
line with Neighbour’s consultation model, which emphasises the importance of connecting and 271 
summarizing.47  272 
Exploring the person's priorities, be it what they have looked forward to, or missed, most during 273 
the current pandemic, can help to contextualize the importance of the vaccination programme 274 
as a collective effort to enable society to come out of lockdown, reverse restrictions, and 275 
minimise economic hardships.  276 
 277 
One of the key difficulties can be communicating risk, for example, the risk of developing 278 
severe infection from covid-19 versus the risk of developing symptoms following vaccination. 279 
Understanding patients’ perceptions of risk and health beliefs is key to establish a shared 280 
dialogue through which HCWs can discuss data clearly using simplified language where 281 
appropriate. Educating patients on the dynamic, evolving and at times uncertain nature of 282 
scientific evidence is also imperative, especially in the context of covid-19 and vaccines. 283 
Another complex situation arises when HCWs are faced with exploring conspiracy theories in 284 
relation to covid-19 or the vaccination programme; the efforts of debunking myths may become 285 
very challenging, and so it can be helpful to find common ground, pick the relevant battles and 286 
continuously refer to agreed guidance among experts.35 287 
 288 
 289 
Box 5 Individual-level interventions for healthcare workers45 290 
 Educational online or written material 291 
 Specialist immunization clinics 292 
 Tailored education 293 
 ‘Elicit-share-elicit’ approach 294 
 Active listening 295 
 Motivational interviewing  296 
 297 
Box 6 Top tips for HCWs communicating with vaccine-hesitant patients 38 298 
 Be aware of cultural and emotional differences 299 
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 Recognize the unique contexts in their environments with difficulties in accessing 300 
healthcare and adhering to public health guidance 301 
 Provide clear and up-to-date guidance  302 
 Repeatedly check understanding  303 
 Adjust styles for differing literacy, education and language levels 304 
 Have reliable, up to date and accessible sources of information on-hand 305 
 Avoid using jargon and stigmatising language 306 





Box 7 Examples of online resources   312 
 313 
NHS Choices: Coronavirus vaccine https://www.nhs.uk/conditions/vaccinations/ 314 
 315 
Coronavirus (COVID-19) Resource Centre https://coronavirusresources.phe.gov.uk/covid-316 
19-vaccine/resources/  317 
 318 
Vaccine Knowledge Project https://vk.ovg.ox.ac.uk/vk/ 319 
 320 
Video by Gavi the Vaccine Alliance: four types of vaccines and how they work  321 
https://www.youtube.com/watch?v=lFjIVIIcCvc 322 
 323 
WHO Global Vaccine Safety https://www.who.int/vaccine_safety/en/ 324 
 325 
US Centres for Disease Control and Prevention: Vaccines and Immunisations 326 
https://www.cdc.gov/vaccines/covid-19/index.html 327 
 328 
The covid-19 Vaccine Communication Handbook https://hackmd.io/@scibehC19vax/home 329 
 330 
Johns Hopkins Medicine https://www.hopkinsmedicine.org/health/conditions-and-331 
diseases/coronavirus/is-the-covid19-vaccine-safe 332 
 333 
British Medical Association – covid-19: how to communicate with different groups about the 334 
vaccine https://www.bma.org.uk/advice-and-support/covid-19/vaccines/covid-19-how-to-335 
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• Do you have a local policy for identifying and engaging vaccine-hesitant patients in general 341 
and specifically covid-19 vaccine hesitancy? 342 
• What strategies have you used to increase vaccine uptake in your facility and how have you 343 
monitored their impact? 344 




How patients were involved in the creation of this article 349 
A patient read the manuscript and provided feedback on the relevance and usefulness of the 350 
recommendations. The patient specifically requested that we also discuss the root causes of 351 
low take-up of vaccine among ethnic minorities including wider determinants of health.  352 
 353 
How this article was made 354 
This article uses best available evidence, recent research papers, the latest advice from 355 
the World Health Organization (WHO) and expert opinion.  356 
We searched systematic reviews, other relevant published research and latest guidelines using 357 
MEDLINE, EMBASE and Google Scholar. Additional resources were drawn from our 358 
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